

# Qinjian Zhao

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9821843/publications.pdf>

Version: 2024-02-01

91  
papers

2,930  
citations

172457

29  
h-index

197818

49  
g-index

93  
all docs

93  
docs citations

93  
times ranked

3743  
citing authors

#	ARTICLE	IF	CITATIONS
1	Understanding COVID-19 vaccine demand and hesitancy: A nationwide online survey in China. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008961.	3.0	473
2	Virus-like particle-based human vaccines: quality assessment based on structural and functional properties. <i>Trends in Biotechnology</i> , 2013, 31, 654-663.	9.3	166
3	The development of a recombinant hepatitis E vaccine HEV 239. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 908-914.	3.3	99
4	Escherichia coli-derived virus-like particles in vaccine development. <i>Npj Vaccines</i> , 2017, 2, 3.	6.0	88
5	Hepatitis E vaccine development. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 823-827.	3.3	85
6	Disassembly and reassembly of human papillomavirus virus-like particles produces more virion-like antibody reactivity. <i>Virology Journal</i> , 2012, 9, 52.	3.4	83
7	COVID-19 vaccination intention and vaccine characteristics influencing vaccination acceptance: a global survey of 17 countries. <i>Infectious Diseases of Poverty</i> , 2021, 10, 122.	3.7	77
8	Replication, pathogenicity, and transmission of SARS-CoV-2 in minks. <i>National Science Review</i> , 2021, 8, nwaa291.	9.5	72
9	Robust manufacturing and comprehensive characterization of recombinant hepatitis E virus-like particles in Hecolin <sup>®</sup> . <i>Vaccine</i> , 2014, 32, 4039-4050.	3.8	71
10	Disassembly and reassembly improves morphology and thermal stability of human papillomavirus type 16 virus-like particles. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2012, 8, 1182-1189.	3.3	67
11	Evaluation of the Thermal Stability of Gardasil <sup>®</sup> . <i>Hum Vaccin</i> , 2006, 2, 147-154.	2.4	60
12	Calcium phosphate nanoparticles as a new generation vaccine adjuvant. <i>Expert Review of Vaccines</i> , 2017, 16, 895-906.	4.4	59
13	Hepatitis E virus: neutralizing sites, diagnosis, and protective immunity. <i>Reviews in Medical Virology</i> , 2012, 22, 339-349.	8.3	58
14	Molecular and functional analysis of monoclonal antibodies in support of biologics development. <i>Protein and Cell</i> , 2018, 9, 74-85.	11.0	57
15	A recombinant spike protein subunit vaccine confers protective immunity against SARS-CoV-2 infection and transmission in hamsters. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	56
16	Characterization of virus-like particles in GARDASIL <sup>®</sup> by cryo transmission electron microscopy. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 734-739.	3.3	53
17	SARS-CoV-2 spike produced in insect cells elicits high neutralization titres in non-human primates. <i>Emerging Microbes and Infections</i> , 2020, 9, 2076-2090.	6.5	53
18	Protection against Lethal Enterovirus 71 Challenge in Mice by a Recombinant Vaccine Candidate Containing a Broadly Cross-Neutralizing Epitope within the VP2 EF Loop. <i>Theranostics</i> , 2014, 4, 498-513.	10.0	52

#	ARTICLE	IF	CITATIONS
19	Global vaccine action plan lessons learned I: Recommendations for the next decade. <i>Vaccine</i> , 2020, 38, 5364-5371.	3.8	50
20	Maturation of Recombinant Hepatitis B Virus Surface Antigen Particles. <i>Hum Vaccin</i> , 2006, 2, 174-180.	2.4	49
21	Cross-neutralizing antibodies bind a SARS-CoV-2 cryptic site and resist circulating variants. <i>Nature Communications</i> , 2021, 12, 5652.	12.8	49
22	Multidimensional social and cultural norms influencing HPV vaccine hesitancy in Asia. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 1611-1622.	3.3	48
23	Toolbox for Non-Intrusive Structural and Functional Analysis of Recombinant VLP Based Vaccines: A Case Study with Hepatitis B Vaccine. <i>PLoS ONE</i> , 2012, 7, e33235.	2.5	46
24	Selection and Characterization of Murine Monoclonal Antibodies to <i>Staphylococcus aureus</i> Iron-Regulated Surface Determinant B with Functional Activity In Vitro and In Vivo. <i>Vaccine Journal</i> , 2009, 16, 1095-1104.	3.1	39
25	Lessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteins. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 1277-1292.	3.3	39
26	Bacteria expressed hepatitis E virus capsid proteins maintain virion-like epitopes. <i>Vaccine</i> , 2014, 32, 2859-2865.	3.8	36
27	Antigenic determinants of hepatitis E virus and vaccine-induced immunogenicity and efficacy. <i>Journal of Gastroenterology</i> , 2013, 48, 159-168.	5.1	34
28	Improved characteristics and protective efficacy in an animal model of E. coli-derived recombinant double-layered rotavirus virus-like particles. <i>Vaccine</i> , 2014, 32, 1921-1931.	3.8	34
29	Serological survey of neutralizing antibodies to eight major enteroviruses among healthy population. <i>Emerging Microbes and Infections</i> , 2018, 7, 1-15.	6.5	33
30	In-depth process understanding of RECOMBIVAX HB <sup>®</sup> maturation and potential epitope improvements with redox treatment: Multifaceted biochemical and immunochemical characterization. <i>Vaccine</i> , 2011, 29, 7936-7941.	3.8	31
31	Real time monitoring of antigenicity development of HBsAg virus-like particles (VLPs) during heat- and redox-treatment. <i>Biochemical and Biophysical Research Communications</i> , 2011, 408, 447-453.	2.1	30
32	Real-time stability of a hepatitis E vaccine (Hecolin <sup>®</sup> ) demonstrated with potency assays and multifaceted physicochemical methods. <i>Vaccine</i> , 2016, 34, 5871-5877.	3.8	26
33	Rational design of a triple-type human papillomavirus vaccine by compromising viral-type specificity. <i>Nature Communications</i> , 2018, 9, 5360.	12.8	25
34	Utilizing ELISA to Monitor Protein-Protein Interaction. <i>Methods in Molecular Biology</i> , 2015, 1278, 341-352.	0.9	25
35	The C-Terminal Arm of the Human Papillomavirus Major Capsid Protein Is Immunogenic and Involved in Virus-Host Interaction. <i>Structure</i> , 2016, 24, 874-885.	3.3	24
36	Determination of picomolar equilibrium dissociation constants in solution by enzyme-linked immunosorbent assay with fluorescence detection. <i>Analytical Biochemistry</i> , 2005, 347, 159-161.	2.4	23

#	ARTICLE	IF	CITATIONS
37	Visualization of discrete L1 oligomers in human papillomavirus 16 virus-like particles by gel electrophoresis with Coomassie staining. <i>Journal of Virological Methods</i> , 2005, 127, 133-140.	2.1	22
38	Current issues facing the introduction of human papillomavirus vaccine in China and future prospects. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 1533-1540.	3.3	22
39	Surface Phosphophilicity of Aluminum-Containing Adjuvants Probed by Their Efficiency for Catalyzing the $Pi-O$ Bond Cleavage with Chromogenic and Fluorogenic Substrates. <i>Analytical Biochemistry</i> , 2001, 295, 76-81.	2.4	21
40	Comparable quality attributes of hepatitis E vaccine antigen with and without adjuvant adsorption-dissolution treatment. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 1129-1139.	3.3	21
41	Chinese mothers' intention to vaccinate daughters against human papillomavirus (HPV), and their vaccine preferences: a study in Fujian Province. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 304-315.	3.3	20
42	Pairwise antibody footprinting using surface plasmon resonance technology to characterize human papillomavirus type 16 virus-like particles with direct anti-HPV antibody immobilization. <i>Journal of Immunological Methods</i> , 2013, 388, 1-7.	1.4	19
43	Expanded strain coverage for a highly successful public health tool: Prophylactic 9-valent human papillomavirus vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 2280-2291.	3.3	19
44	Hepatitis E Vaccine to Prevent Morbidity and Mortality During Epidemics. <i>Open Forum Infectious Diseases</i> , 2014, 1, ofu098.	0.9	17
45	A novel vaccine candidate based on chimeric virus-like particle displaying multiple conserved epitope peptides induced neutralizing antibodies against EBV infection. <i>Theranostics</i> , 2020, 10, 5704-5718.	10.0	17
46	A human monoclonal antibody against HPV16 recognizes an immunodominant and neutralizing epitope partially overlapping with that of H16.V5. <i>Scientific Reports</i> , 2016, 6, 19042.	3.3	16
47	Rational design of a multi-valent human papillomavirus vaccine by capsomere-hybrid co-assembly of virus-like particles. <i>Nature Communications</i> , 2020, 11, 2841.	12.8	16
48	Prophylactic Hepatitis E Vaccines: Antigenic Analysis and Serological Evaluation. <i>Viruses</i> , 2020, 12, 109.	3.3	16
49	COVID-19 Anti-Vaccine Sentiments: Analyses of Comments from Social Media. <i>Healthcare (Switzerland)</i> , 2021, 9, 1530.	2.0	16
50	Development of an enzyme-linked immunospot assay for determination of rotavirus infectivity. <i>Journal of Virological Methods</i> , 2014, 209, 7-14.	2.1	15
51	In Vivo Time-Related Evaluation of a Therapeutic Neutralization Monoclonal Antibody against Lethal Enterovirus 71 Infection in a Mouse Model. <i>PLoS ONE</i> , 2014, 9, e109391.	2.5	14
52	A highly conserved epitope-vaccine candidate against varicella-zoster virus induces neutralizing antibodies in mice. <i>Vaccine</i> , 2016, 34, 1589-1596.	3.8	13
53	Quantitative and epitope-specific antigenicity analysis of the human papillomavirus 6 capsid protein in aqueous solution or when adsorbed on particulate adjuvants. <i>Vaccine</i> , 2016, 34, 4422-4428.	3.8	12
54	Altered antigenicity and immunogenicity of human papillomavirus virus-like particles in the presence of thimerosal. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019, 141, 221-231.	4.3	12

#	ARTICLE	IF	CITATIONS
55	Functional assessment and structural basis of antibody binding to human papillomavirus capsid. <i>Reviews in Medical Virology</i> , 2016, 26, 115-128.	8.3	11
56	Neutralization sites of human papillomavirus-6 relate to virus attachment and entry phase in viral infection. <i>Emerging Microbes and Infections</i> , 2019, 8, 1721-1733.	6.5	11
57	Prophylactic Hepatitis E Vaccine. <i>Advances in Experimental Medicine and Biology</i> , 2016, 948, 223-246.	1.6	10
58	Epitope clustering analysis for vaccine-induced human antibodies in relationship to a panel of murine monoclonal antibodies against HPV16 viral capsid. <i>Vaccine</i> , 2018, 36, 6761-6771.	3.8	10
59	Demonstration of real-time and accelerated stability of hepatitis E vaccine with a combination of different physicochemical and immunochemical methods. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 177, 112880.	2.8	10
60	Impact of naturally occurring variation in the human papillomavirus 52 capsid proteins on recognition by type-specific neutralising antibodies. <i>Journal of General Virology</i> , 2019, 100, 237-245.	2.9	10
61	Development of a skin- and neuro-attenuated live vaccine for varicella. <i>Nature Communications</i> , 2022, 13, 824.	12.8	10
62	Chinese parents' intentions to vaccinate their children against SARS-CoV-2 infection and vaccine preferences. <i>Human Vaccines and Immunotherapeutics</i> , 2024, 17, 4806-4815.	3.3	10
63	Toward the development of monoclonal antibody-based assays to probe virion-like epitopes in hepatitis B vaccine antigen. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 1013-1023.	3.3	9
64	Development of a varicella-zoster virus neutralization assay using a glycoprotein K antibody enzyme-linked immunosorbent spot assay. <i>Journal of Virological Methods</i> , 2014, 200, 10-14.	2.1	9
65	Serological Evaluation of Immunity to the Varicella-Zoster Virus Based on a Novel Competitive Enzyme-Linked Immunosorbent Assay. <i>Scientific Reports</i> , 2016, 6, 20577.	3.3	9
66	Viral neutralization by antibody-imposed physical disruption. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 26933-26940.	7.1	9
67	Specific interaction between hnRNP H and HPV16 L1 proteins: Implications for late gene auto-regulation enabling rapid viral capsid protein production. <i>Biochemical and Biophysical Research Communications</i> , 2013, 430, 1047-1053.	2.1	8
68	Prophylaxis against hepatitis E: at risk populations and human vaccines. <i>Expert Review of Vaccines</i> , 2016, 15, 815-827.	4.4	8
69	Hepatitis E vaccine candidate harboring a non-particulate immunogen of E2 fused with CRM197 fragment A. <i>Antiviral Research</i> , 2019, 164, 154-161.	4.1	8
70	A prophylactic effect of aluminium-based adjuvants against respiratory viruses via priming local innate immunity. <i>Emerging Microbes and Infections</i> , 2022, 11, 914-925.	6.5	8
71	Detection of subtle differences in analogous viral capsid proteins by allowing unrestricted specific interaction in solution competition ELISA. <i>Journal of Virological Methods</i> , 2016, 236, 1-4.	2.1	7
72	Multifaceted characterization of recombinant protein-based vaccines: An immunochemical toolbox for epitope-specific analyses of the hepatitis E vaccine. <i>Vaccine</i> , 2018, 36, 7650-7658.	3.8	7

#	ARTICLE	IF	CITATIONS
73	Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes. <i>Journal of Virology</i> , 2020, 94, .	3.4	7
74	The study of seroprevalence of hepatitis E virus and an investigation into the lifestyle behaviours of the aborigines in Malaysia. <i>Zoonoses and Public Health</i> , 2020, 67, 263-270.	2.2	7
75	Functional epitopes on hepatitis E virions and recombinant capsids are highly conformation-dependent. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 1554-1564.	3.3	7
76	Carbohydrate-containing nanoparticles as vaccine adjuvants. <i>Expert Review of Vaccines</i> , 2021, 20, 797-810.	4.4	7
77	Evaluation of immunity to varicella zoster virus with a novel double antigen sandwich enzyme-linked immunosorbent assay. <i>Applied Microbiology and Biotechnology</i> , 2016, 100, 9321-9329.	3.6	6
78	Identification of Strategic Residues at the Interface of Antigen-Antibody Interactions by In Silico Mutagenesis. <i>Interdisciplinary Sciences, Computational Life Sciences</i> , 2018, 10, 438-448.	3.6	6
79	Simultaneous <i>in situ</i> visualization and quantitation of dual antigens adsorbed on adjuvants using high content analysis. <i>Nanomedicine</i> , 2019, 14, 2535-2548.	3.3	5
80	The Risk of Transfusion-Transmitted Hepatitis E Virus: Evidence from Seroprevalence Screening of Blood Donations. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2022, 38, 145-152.	0.6	5
81	Recombinant Virus-like Particle Protein Vaccines. , 2015, , 81-112.		4
82	Production of Influenza Virus HA1 Harboring Native-Like Epitopes by <i>Pichia pastoris</i> . <i>Applied Biochemistry and Biotechnology</i> , 2016, 179, 1275-1289.	2.9	4
83	Capsid destabilization and epitope alterations of human papillomavirus 18 in the presence of thimerosal. <i>Journal of Pharmaceutical Analysis</i> , 2020, 11, 617-627.	5.3	4
84	Structural Basis for the Shared Neutralization Mechanism of Three Classes of Human Papillomavirus Type 58 Antibodies with Disparate Modes of Binding. <i>Journal of Virology</i> , 2021, 95, .	3.4	4
85	HIV-1 Membrane-Proximal External Region Fused to Diphtheria Toxin Domain-A Elicits 4E10-Like Antibodies in Mice. <i>Immunology Letters</i> , 2019, 213, 30-38.	2.5	3
86	A Bacterially Expressed SARS-CoV-2 Receptor Binding Domain Fused With Cross-Reacting Material 197 A-Domain Elicits High Level of Neutralizing Antibodies in Mice. <i>Frontiers in Microbiology</i> , 2022, 13, 854630.	3.5	3
87	Microtiter Plate-Based Differential Scanning Fluorimetry: A High-Throughput Method for Efficient Formulation Development. <i>Journal of Pharmaceutical Sciences</i> , 2022, 111, 2397-2403.	3.3	3
88	The 2016 Lasker-DeBakey Clinical Medical Research Award: Innovative hepatitis C virus (HCV) replicons leading to drug development for hepatitis C cure. <i>Science China Life Sciences</i> , 2016, 59, 1198-1201.	4.9	1
89	A stepwise docking molecular dynamics approach for simulating antibody recognition with substantial conformational changes. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 710-720.	4.1	1
90	My passion for biologics: From active sites to life-saving and public health. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3430-3434.	3.3	0

#	ARTICLE	IF	CITATIONS
91	In situ analysis of biomolecular interactions on nano/microparticles in formulations. Journal of Pharmaceutical and Biomedical Analysis, 2021, 201, 114130.	2.8	0